These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 15907148)

  • 1. Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders.
    Siddiqui MA; Scott LJ
    Drugs; 2005; 65(8):1161-77. PubMed ID: 15907148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders.
    Croom KF; McCormack PL
    BioDrugs; 2008; 22(2):121-36. PubMed ID: 18345709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2007; 25(12):1007-29. PubMed ID: 18047387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders.
    Di Minno G
    Blood Rev; 2015 Jun; 29 Suppl 1():S26-33. PubMed ID: 26073366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant activated factor VII: 30 years of research and innovation.
    Hedner U
    Blood Rev; 2015 Jun; 29 Suppl 1():S4-8. PubMed ID: 26073368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
    Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
    Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors.
    Santagostino E; Escobar M; Ozelo M; Solimeno L; Arkhammar P; Lee HY; Rosu G; Giangrande P
    Blood Rev; 2015 Jun; 29 Suppl 1():S9-18. PubMed ID: 26073369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NovoSeven (recombinant factor VIIa) for the treatment of bleeding episodes and perioperative management in patients with Glanzmann's thrombasthenia.
    Franchini M; Lippi G
    Expert Rev Hematol; 2014 Dec; 7(6):733-40. PubMed ID: 25387838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders.
    Shima M
    Ann Hematol; 2024 Aug; 103(8):2647-2658. PubMed ID: 37391649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.
    Ducore J; Lawrence JB; Simpson M; Boggio L; Bellon A; Burggraaf J; Stevens J; Moerland M; Frieling J; Reijers J; Wang M
    Haemophilia; 2017 Nov; 23(6):844-851. PubMed ID: 28984010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors.
    Matino D; Makris M; Dwan K; D'Amico R; Iorio A
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004449. PubMed ID: 26677005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of recombinant activated factor VII in patients with acquired haemophilia.
    Tiede A; Amano K; Ma A; Arkhammar P; El Fegoun SB; Rosholm A; Seremetis S; Baudo F
    Blood Rev; 2015 Jun; 29 Suppl 1():S19-25. PubMed ID: 26073365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eptacog beta: a novel recombinant human factor VIIa for the treatment of hemophilia A and B with inhibitors.
    Biron-Andreani C; Schved JF
    Expert Rev Hematol; 2019 Jan; 12(1):21-28. PubMed ID: 30577721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant Activated Factor VII (Eptacog Alfa Activated, NovoSeven®) in Patients with Rare Congenital Bleeding Disorders. A Systematic Review on its Use in Surgical Procedures.
    Di Minno MND; Ambrosino P; Myasoedova V; Amato M; Ventre I; Tremoli E; Minno AD
    Curr Pharm Des; 2017; 23(7):1125-1131. PubMed ID: 28034354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of recombinant factor VIIa in hereditary bleeding disorders.
    Poon MC
    Curr Opin Hematol; 2001 Sep; 8(5):312-8. PubMed ID: 11604567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recombinant activated factor VII in paediatric practice. Universal hemostatic agent?].
    Monpoux F; Chambost H; Haouy S; Benadiba J; Sirvent N
    Arch Pediatr; 2010 Aug; 17(8):1210-9. PubMed ID: 20598867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. To general haemostasis--the evidence-based route.
    Erhardtsen E
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():47-52. PubMed ID: 12214148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into the management of bleeding disorders.
    Escolar G
    Drug News Perspect; 2004 May; 17(4):285-8. PubMed ID: 15334177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective.
    Miesbach W; Carcao M; Mahlangu J; Dargaud Y; Jimenez-Yuste V; Hermans C
    Haemophilia; 2024 Mar; 30(2):257-266. PubMed ID: 38317441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.
    Wang M; Lawrence JB; Quon DV; Ducore J; Simpson ML; Boggio LN; Mitchell IS; Yuan G; Alexander WA; Schved JF
    Haemophilia; 2017 Nov; 23(6):832-843. PubMed ID: 28776894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.